This website is intended for healthcare professionals only

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Share this article

Follow by Email
Facebook
Twitter

Cancer treatment gets approval


11 April, 2008  

Alimtra has received European approval for histologically-based use in the first-line treatment of advanced non-small cell lung cancer (NSCLC), Eli Lilly and Company has announced.

The approval comes after a positive response from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP).

The body specifically approved pemetrexed in combination with cisplatin as a first-line treatment for NSCLC patients with other than predominantly squamous cell histology.

Richard Gaynor, of Lilly, said: “This approval opens the door for a novel, tailored approach based on histology or tissue type

“Our hope is that this study provides physicians with a powerful tool for choosing the right drug for the right patient that leads to optimal treatment results.”

The approval comes after a Phase III randomized study that looked at pemetrexed plus cisplatin versus GEMZAR(R) (gemcitabine HCl for injection) plus cisplatin.

The lead investigator of the study, Giorgio Scagliotti, said: “This study provides further evidence of the need to use a tailored approach to treating lung cancer patients, rather than simply using a particular medicine because of the treatment stage.”

Copyright © PA Business 2008

European Medicines Agency